Advertisement

Afib

US FDA Fast Tracks Antithrombotic from BMS and J&J

May 26th, 2023|Categories: Featured, Industry News|Tags: , , , , |

Johnson & Johnson and Bristol Meyer’s Squibb’s (BMS’s) antithrombotic milvexian has been fast tracked by the US Food and Drug Administration for three indications, according to the companies. The drug received the designation for the drug for stroke, atrial fibrillation, and acute coronary syndrome. Fast track designation is often granted for drugs that address medical conditions with limited treatment options.

Go to Top